These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17383421)

  • 21. Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C.
    Tohra SK; Taneja S; Ghosh S; Sharma BK; Duseja A; Dhiman RK; Das A; Chawla YK
    Dig Dis Sci; 2011 Aug; 56(8):2449-55. PubMed ID: 21706207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C.
    Sanjo M; Saito T; Ishii R; Nishise Y; Haga H; Okumoto K; Ito J; Watanabe H; Saito K; Togashi H; Fukuda K; Imai Y; El-Shamy A; Deng L; Shoji I; Hotta H; Kawata S
    J Med Virol; 2010 Aug; 82(8):1364-70. PubMed ID: 20572079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C.
    You BC; Kim YS; Kim Hi; Kim SH; Park SS; Seo YR; Kim SG; Lee SW; Kim HS; Jeong SW; Jang JY; Kim BS
    Clin Mol Hepatol; 2012 Sep; 18(3):272-8. PubMed ID: 23091807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
    Qing J; Luo R; Wang Y; Nong J; Wu M; Shao Y; Tang R; Yu X; Yin Z; Sun Y
    Antiviral Res; 2016 Feb; 126():43-54. PubMed ID: 26724382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy.
    Vuillermoz I; Khattab E; Sablon E; Ottevaere I; Durantel D; Vieux C; Trepo C; Zoulim F
    J Med Virol; 2004 Sep; 74(1):41-53. PubMed ID: 15258967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutations Identified in the Hepatitis C Virus (HCV) Polymerase of Patients with Chronic HCV Treated with Ribavirin Cause Resistance and Affect Viral Replication Fidelity.
    Mejer N; Fahnøe U; Galli A; Ramirez S; Weiland O; Benfield T; Bukh J
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.
    Berak H; Laskus T; Kołakowska-Rządzka A; Wasilewski M; Stańczak JJ; Bardadin K; Walewska-Zielecka B; Horban A
    Adv Med Sci; 2014 Sep; 59(2):261-5. PubMed ID: 25117425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus.
    Kneteman NM; Howe AY; Gao T; Lewis J; Pevear D; Lund G; Douglas D; Mercer DF; Tyrrell DL; Immermann F; Chaudhary I; Speth J; Villano SA; O'Connell J; Collett M
    Hepatology; 2009 Mar; 49(3):745-52. PubMed ID: 19072827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients.
    Le Pogam S; Seshaadri A; Ewing A; Kang H; Kosaka A; Yan JM; Berrey M; Symonds B; De La Rosa A; Cammack N; Nájera I
    J Infect Dis; 2010 Nov; 202(10):1510-9. PubMed ID: 20942646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment.
    Muñoz de Rueda P; Fuentes Rodríguez JM; Quiles Pérez R; Gila Medina A; Martín Álvarez AB; Casado Ruíz J; Ruíz Extremera A; Salmerón J
    World J Gastroenterol; 2017 Jul; 23(25):4538-4547. PubMed ID: 28740342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.
    Gane EJ; Stedman CA; Hyland RH; Ding X; Svarovskaia E; Symonds WT; Hindes RG; Berrey MM
    N Engl J Med; 2013 Jan; 368(1):34-44. PubMed ID: 23281974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.
    Rosen I; Kori M; Eshach Adiv O; Yerushalmi B; Zion N; Shaoul R
    World J Gastroenterol; 2013 Feb; 19(7):1098-103. PubMed ID: 23467199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
    Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
    N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy.
    Veillon P; Payan C; Le Guillou-Guillemette H; Gaudy C; Lunel F
    World J Gastroenterol; 2007 Feb; 13(8):1195-203. PubMed ID: 17451199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA.
    Kanda T; Yokosuka O; Imazeki F; Tanaka M; Shino Y; Shimada H; Tomonaga T; Nomura F; Nagao K; Ochiai T; Saisho H
    J Viral Hepat; 2004 Nov; 11(6):479-87. PubMed ID: 15500548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of interferon-ribavirin treatment on hepatitis C virus (HCV) protease quasispecies diversity in HIV- and HCV-coinfected patients.
    Chary A; Winters MA; Kottilil S; Murphy AA; Polis MA; Holodniy M
    J Infect Dis; 2010 Sep; 202(6):889-93. PubMed ID: 20677940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction.
    Di Marco V; Ferraro D; Almasio P; Vaccaro A; Parisi P; Cappello M; Cino N; Di Stefano R; Craxì A
    J Viral Hepat; 2002 Sep; 9(5):354-9. PubMed ID: 12225330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
    Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.
    Oze T; Hiramatsu N; Yakushijin T; Miyazaki M; Iio S; Oshita M; Hagiwara H; Mita E; Inui Y; Hijioka T; Inada M; Tamura S; Yoshihara H; Inoue A; Imai Y; Miyagi T; Yoshida Y; Tatsumi T; Kanto T; Kasahara A; Hayashi N; Takehara T
    J Gastroenterol; 2014 Apr; 49(4):737-47. PubMed ID: 23689988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
    Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
    J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.